Background: Accurate nodal restaging is becoming clinically more important in patients with locally advanced rectal cancer (LARC) with the emergence of organ-preserving treatment after a good response to neoadjuvant chemoradiotherapy (nCRT). Purpose: To evaluate the accuracy of MRI in identifying negative N status (ypN0 patients) in LARC after nCRT. Material and Methods: 191 patients with LARC underwent MRI before and 6–8 weeks after nCRT and subsequent total mesorectal excision. Short-axis diameter of mesorectal lymph nodes was evaluated on the high resolution T2-weighted images to compare MRI restaging with histopathology. Results: 146 and 45 patients had a negative N status (ypN0) and positive N status (ypN + ), respectively. On restaging MRI, the 70 % reduction in size of the largest node was associated with an area under the curve (AUC) of 0.818 to predict ypN0 stage, with a sensitivity of 93.3 % and a negative predictive value (NPV) of 95.4 %. No nodes were observed in 38 pts (37 pts ypN0 and 1 patient ypN + ), with sensitivity and NPV of nodes disappearance for ypN0 stage of 93.3 % and 92.5 % respectively. A 2.2 mm cut-off in short-axis diameter was associated with an AUC of 0.83 for the prediction of ypN0 nodal stage, with sensitivity and NPV of 79,5% and 91.1 % respectively. Conclusion: A reduction in size of 70 % of the largest limph-node on MRI at rectal cancer restaging has high sensitivity and NPV for prediction of ypN0 stage after nCRT. The high NPV of node disappearance and of a ≤ 2.2 mm short-axis diameter is confirmed.

Barbaro, B., Carafa, M. R. P., Minordi, L. M., Testa, P., Tatulli, G., Carano, D., Fiorillo, C., Chiloiro, G., Romano, A., Valentini, V., Gambacorta, M. A., Magnetic resonance imaging for assessment of rectal cancer nodes after chemoradiotherapy: A single center experience, <<RADIOTHERAPY AND ONCOLOGY>>, 2024; 193 (NA): N/A-N/A. [doi:10.1016/j.radonc.2024.110124] [https://hdl.handle.net/10807/339258]

Magnetic resonance imaging for assessment of rectal cancer nodes after chemoradiotherapy: A single center experience

Barbaro, Brunella;Minordi, Laura Maria;Tatulli, Giulia;Carano, Davide;Fiorillo, Claudio;Chiloiro, Giuditta;Valentini, Vincenzo;Gambacorta, Maria Antonietta
2024

Abstract

Background: Accurate nodal restaging is becoming clinically more important in patients with locally advanced rectal cancer (LARC) with the emergence of organ-preserving treatment after a good response to neoadjuvant chemoradiotherapy (nCRT). Purpose: To evaluate the accuracy of MRI in identifying negative N status (ypN0 patients) in LARC after nCRT. Material and Methods: 191 patients with LARC underwent MRI before and 6–8 weeks after nCRT and subsequent total mesorectal excision. Short-axis diameter of mesorectal lymph nodes was evaluated on the high resolution T2-weighted images to compare MRI restaging with histopathology. Results: 146 and 45 patients had a negative N status (ypN0) and positive N status (ypN + ), respectively. On restaging MRI, the 70 % reduction in size of the largest node was associated with an area under the curve (AUC) of 0.818 to predict ypN0 stage, with a sensitivity of 93.3 % and a negative predictive value (NPV) of 95.4 %. No nodes were observed in 38 pts (37 pts ypN0 and 1 patient ypN + ), with sensitivity and NPV of nodes disappearance for ypN0 stage of 93.3 % and 92.5 % respectively. A 2.2 mm cut-off in short-axis diameter was associated with an AUC of 0.83 for the prediction of ypN0 nodal stage, with sensitivity and NPV of 79,5% and 91.1 % respectively. Conclusion: A reduction in size of 70 % of the largest limph-node on MRI at rectal cancer restaging has high sensitivity and NPV for prediction of ypN0 stage after nCRT. The high NPV of node disappearance and of a ≤ 2.2 mm short-axis diameter is confirmed.
2024
Inglese
Barbaro, B., Carafa, M. R. P., Minordi, L. M., Testa, P., Tatulli, G., Carano, D., Fiorillo, C., Chiloiro, G., Romano, A., Valentini, V., Gambacorta, M. A., Magnetic resonance imaging for assessment of rectal cancer nodes after chemoradiotherapy: A single center experience, <<RADIOTHERAPY AND ONCOLOGY>>, 2024; 193 (NA): N/A-N/A. [doi:10.1016/j.radonc.2024.110124] [https://hdl.handle.net/10807/339258]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/339258
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 5
social impact